Nutra Pharma Corp. (OTCPINK: NPHC) saw its share volume skyrocket on June 12th with 40,578,885 shares exchanging hands, 43 times higher than its three month daily average volume of 945,114 shares.
This spike in volume comes after Nutra Pharma Corp, a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that MyNyloxin.com, a new company that has the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin®, has signed contracts to begin airing television commercials beginning June 23rd. The advertisements focus on the benefits of Nyloxin®. The first contract includes over 30,000 spots to run throughout the Southeast Region from Comcast and AT&T U-Verse Cable providers. The ads are scheduled to run on the following channels: GOLF, LMN, CNBC, FOXN, MSNBC, NBCS, ESPN, ESPN2, TNT, FOXS, TWC, CNN, HALL, HGTV, TLC, HLN and LIFE.
"MyNyloxin has been working diligently with our creative team to get these commercials completed," stated Dalton Johnson, CEO of MyNyloxin.com. "The initial rollout is throughout the South Florida market with eventual expansion into the Northeast and California markets in the coming months," he continued. "We believe that these advertisements will capture the imagination of potential customers that need access to a superior pain relief product and should help grow sales in the short term," he concluded.
"MyNyloxin Distributors have been consistently increasing the public awareness of Nyloxin," said Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "They will be targeting these commercials in areas that are expected to provide the widest market for our pain relief products, with the eventual rollout to the national stage over the next several months," he concluded.
NPHC closed the day at $.0096, 31.51% higher than its previous close of $.0073.
PennyPickAlerts.com is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:
BrainStorm Cell Therapeutics Initiates Study Of Autism On Mice
BrainStorm Cell Therapeutics, Inc. (OTCQB: BCLI) saw its share volume explode on June 12th with 4,040,131 shares exchanging hands, five times higher than its three month daily average volume of 790,125 shares.
This uptick in volume comes after BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that it has initiated a study in a mouse model of autism at the Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, under the direction of Professor Daniel Offen. The study will explore the effects of the company's "MSC-NTF" cells on mouse behavior.
The study, which will be conducted using the BTBR mouse model for autism, will investigate repetitive behavior, increased cognitive flexibility and improved sociability in mice after administration of a single intracerebroventricular injection of the cells.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University.
BCLI closed the day at $.348, 12.26% higher than its previous close of $.31.
Fortune Oil & Gas Acquires Manzo Pharmaceuticals, LLC
Fortune Oil & Gas, Inc. (OTCPINK: FOGC) saw its share volume skyrocket on June 12th with 598,627,448 shares exchanging hands, nearly 14 times higher than its three month daily average volume of 43,383,599 shares.
Fortune Oil and Gas announced yesterday that the company has acquired Manzo Pharmaceuticals, LLC, a private firm aiming to become a major force in the pharmaceutical industry. As part of the acquisition, Manzo Pharmaceutical's founder and President, Kenneth Manzo has been appointed CEO and Chairman of Fortune Oil & Gas, Inc.
Manzo Pharmaceuticals, LLC is a specialty pharmaceutical company that is currently developing a range of innovative and affordable formulations for various drugs and supplements with innovative, patient-friendly and affordable solutions. The company is currently engaged in research and development of a patented, groundbreaking remedy that will remove the symptoms of lactose intolerance for months at a time. The company also has a host of other remedies. Some of these products are currently in development, and others are being prepared for release to the public. Of particular interest to many, is a safe and natural solution for babies with colic, gas, and stomach discomfort that will likely be available online by the end of the month.
The company will likely file for a name change in the near future, with the goal of building the Manzo brand and advancing the development and clinical trials of the patented solutions, while releasing several consumer-ready products for sale online, and in retail stores. By targeting illnesses and conditions that effect a large percentage of the population, with unique, patented and effective remedies, Manzo Pharmaceuticals plans to be a driving force in the pharmaceutical industry.
FOGC closed the day at $.001.
Pennypickalerts.com issues momentum alerts on stocks that can provide gains to day traders.
Pennypickalerts.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.
Pennypickalerts.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Pennypickalerts.com is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the Pennypickalerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Pennypickalerts.com believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.pennypickalerts.com
Pennypickalerts.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.